Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 29, 2001

View Archived Issues

Efexor XR, a long-term alternative to benzodiazepines in treating anxiety

Avax granted licensing option for SCID gene therapy technology

Phase II trial of MG-98 in renal cell carcinoma begins

Dexmethylphenidate hydrochloride receives FDA approvable letter for ADHD

Novartis files FDA application for Zometa as treatment for bone metastases

Neurocrine Biosciences expands clinical development efforts during Q2

A promising scaffold for bioartificial liver development

Crucell establishes human antibody agreement with Centocor for treatment of cancer

Medennium's SmartPlug receives E.U. clearance for treatment of dry eyes

SS Pharmaceutical discovers antifungal compounds with improved solubility

Continued progress in clinical programs reported at Guilford

DepoMed highlights recent product developments

Neuron-selective Ca channel blocker discovered at Eisai

Altana reports decisive progress in development of roflumilast and ciclesonide

Selective glucocorticoid receptor modulators described by Pfizer at ACS meeting

UCB's Xyzal receives pan-European approval

GSK presents new PPARgamma agonists during the ongoing ACS meeting

Mixed 5-HT2A and TP-receptor antagonists added at Servier pipeline reported at ACS

Dual PPARgamma/alpha agonists identified at Kotobuki

GSK claims new adenosine A1 agonist formulations for the treatment of pain

AMPA receptor antagonists presented by Kyorin

Natural antibacterial and antitumor agent isolated by Kyowa Hakko

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...